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The human health risk posed by exposure to
persistent organochlorine pollutants, including
polychlorinated dioxins, polychlorinated
dibenzofurans, and polychlorinated biphenyls
(PCBs), present in the food and the environ-
ment is one of widespread concerns through-
out the industrialized world (Hites et al. 2004;
Stellman et al. 2003). Given the absence of
adequate toxicology and carcinogenesis infor-
mation on the vast majority of these classes,
the dioxin toxic equivalency factor (TEF)
approach is currently used worldwide for
assessing and managing the risks posed by
exposure to mixtures of certain dioxin-like
compounds (DLCs) (Ahlborg et al. 1992;
Birnbaum and DeVito 1995; Safe 1990; Van
den Berg et al. 1998). The TEF approach is a
relative potency paradigm that is based on esti-
mates of the potency of dioxin-like effects of
individual chemicals, or a mixture of chemicals
assuming a common mechanism of action
involving binding of the compound(s) to the
aryl hydrocarbon receptor (AhR) (Schmidt
and Bradﬁeld 1996). Moreover, the risk associ-
ated with a mixture of DLCs may be estimated
based on the effects of 2,3,7,8-tetrachloro-
dibenzo-p-dioxin (TCDD), the most potent
member of this class of compounds, and using
a dose metric that is based on the summation
of the mass of each compound in the mixture
after adjustment for its potency relative to that
of TCDD. This concept of potency-adjusted
dose additivity has been evaluated for a num-
ber of end points (DeVito et al. 1997; Hamm
et al. 2003; Toyoshiba et al. 2004) but has
never been evaluated for cancer risk from
chronic/lifetime exposure. Given that assess-
ments of human cancer risk are based in part
on data obtained from rodent carcinogenicity
studies, it is important and appropriate to
assess whether the concept of dose additivity is
valid for the carcinogenicity of a mixture of
DLCs within the context of a rodent cancer
bioassay.
To evaluate the TEF approach for the pre-
diction of cancer risk, the National Toxicology
Program (NTP) conducted multiple 2-year
lifetime rat bioassays to evaluate the chronic
toxicity and carcinogenicity of DLCs and
structurally related PCBs and mixtures of
these compounds. Speciﬁcally we conducted
four 2-year rodent bioassays to test the
hypothesis of dose-additive carcinogenicity of
a defined mixture of DLCs. These studies
were conducted in female Harlan Sprague-
Dawley rats, based on the prior observations of
the carcinogenic sensitivity to TCDD in the
Spartan Sprague-Dawley rat strain (Kociba
et al. 1978). Animals received either TCDD,
PCB-126, 2,3,4,7,8-pentachlorodibenzofuran
(PeCDF), or a mixture of all three com-
pounds. Doses were established using the cur-
rent World Health Organization (WHO) TEF
values (Van den Berg et al. 1998) to provide
doses of the individual chemicals or the mix-
ture estimated to be equivalent to those used in
the TCDD study. The mixture study was
designed such that each compound would
provide a third of the total dioxin toxic equiv-
alents (TEQs) to the mixture. These relative
levels were chosen to maximize statistical
power to test for interactions between the
three compounds. This does not reflect the
relative abundance of each of these com-
pounds in food, the primary medium of
human exposure. However, these three com-
pounds combined do account for approxi-
mately half of the dioxin-like activity found in
human tissues. In this article, we report on the
comparative dose–response modeling of the
increases in incidence of speciﬁc neoplasms in
these studies to test the hypothesis of dose
additivity of carcinogenicity of dioxins within
a deﬁned mixture.
Materials and Methods
Animal use. The animal studies were con-
ducted at Battelle Columbus Laboratories
(Columbus, OH). All studies were conducted
according to Good Laboratory Practices (Food
and Drug Administration 2002). Animals
were obtained from Harlan SD (Indianapolis,
IN) and upon receipt were approximately
6 weeks of age. They were held under quaran-
tine for approximately 2 weeks for health
screening and were approximately 8 weeks of
age at the start of the study. After quarantine,
the animals were randomly assigned to con-
trol or treated groups and permanently iden-
tified by tail tattoo. They were housed five
per cage in solid-bottom polycarbonate cages
(Lab Products, Inc., Maywood, NJ) sus-
pended on stainless steel racks. Filtered room
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Use of the dioxin toxic equivalency factor (TEF) approach in human risk assessments assumes that
the combined effects of dioxin-like compounds in a mixture can be predicted based on a potency-
adjusted dose-additive combination of constituents of the mixture. In this study, we evaluated the
TEF approach in experimental 2-year rodent cancer bioassays with female Harlan Sprague-Dawley
rats receiving 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 3,3´,4,4´,5-pentachlorobiphenyl
(PCB-126), 2,3,4,7,8-pentachlorodibenzofuran (PeCDF), or a mixture of the three compounds.
Statistically based dose–response modeling indicated that the shape of the dose–response curves
for hepatic, lung, and oral mucosal neoplasms was the same in studies of the three individual
chemicals and the mixture. In addition, the dose response for the mixture could be predicted from
a combination of the potency-adjusted doses of the individual compounds. Finally, we showed
that use of the current World Health Organization dioxin TEF values adequately predicted the
increased incidence of liver tumors (hepatocellular adenoma and cholangiocarcinoma) induced by
exposure to the mixture. These data support the use of the TEF approach for dioxin cancer risk
assessments. Key words: carcinogenicity, dioxin, mixtures, PCBs, persistent organochlorine pollu-
tants, polychlorinated biphenyls, POPs, risk assessment, TEF, toxic equivalency factor. Environ
Health Perspect 113:43–48 (2005). doi:10.1289/ehp.7351 available via http://dx.doi.org/ [Online
19 October 2004]air underwent at least 10 changes/hr. Animal
rooms were maintained at 69–75°F with
35–65% relative humidity and 12 hr
light/12 hr dark. Irradiated NTP-2000 pel-
leted feed (Zeigler Bros., Inc., Gardners, PA)
and water were available ad libitum. All ani-
mals were observed twice daily for morbidity
checks and once per month for formal clinical
signs of toxicity; moribund animals were
euthanized and necropsied. The health status
of the animals was monitored by serologic
analysis of serum samples collected from the
study animals and male sentinel rats that were
placed in the study rooms. Serum samples
remained negative for any significant rodent
pathogen. Animal husbandry and handling
were conducted in accordance with the
National Institutes of Health guidelines
(Institute of Laboratory Animal Resources
1996). 
Chemicals. TCDD (lot no. CR82-2-2)
was supplied by IIT Research Institute
(Chicago, IL) and 3,3´,4,4´,5-pentachloro-
biphenyl (PCB-126; lot no. 130494) by
AccuStandard, Inc. (New Haven, CT).
PeCDF (lot no. 080196) was purchased from
Cambridge Isotope Laboratories (Cambridge,
MA). Each chemical was received in one lot
that was used for the entire study. Purity was
determined several times during the study by
gas chromatography/mass spectroscopy
(GC/MS), nuclear magnetic resonance spec-
troscopy, and gas chromatography using ﬂame
ionization detection (PCB-126), electron cap-
ture detection (TCDD), proton and carbon-
13 nuclear magnetic spectroscopy (PeCDF),
and GC/MS (TEF mixture). Purities of
TCDD, PCB-126, and PeCDF were deter-
mined to be approximately 98, 99.51, and
97%, respectively, with no change in purity
observed over the duration of the studies.
Dose formulations were prepared monthly for
gavage administration by mixing the test
chemical in a corn oil vehicle containing
1% USP-grade acetone. The corn oil was ana-
lyzed by potentiometric titration, and the ace-
tone by infrared spectroscopy. Homogeneity
and stability studies of dose formulations
indicated that chemicals could maintain an
acceptable homogeneity for dosing and sta-
bility for 35 days when stored at room tem-
perature. Dose formulations were analyzed at
least every 3 months and were within 10% of
the target concentrations. For the mixture,
the dose formulations were prepared by mix-
ing volumes of the TCDD, PeCDF, and
PCB-126 formulations.
Treatment. Animals were treated by
gavage (2.5 mL/kg), 5 days per week for up to
2 years. Compounds used were TCDD,
PCB-126, PeCDF, or a mixture of these three
compounds. Group sizes for the 2-year
carcinogenicity portion of these studies were
53 animals per dose group except for the 3-ng
TCDD/kg group (n = 54) and the 30 ng PCB-
126/kg group (n = 55). Target doses used for
the individual compound studies were 3, 10,
22, 46, and 100 ng/kg TCDD; 30, 100, 175,
300, 550, and 1,000 ng/kg PCB-126; and 6,
20, 44, 92, and 200 ng/kg PeCDF. The TEF
mixture was composed of equal ratios (1:1:1)
of TEQs for TCDD, PCB-126, and PeCDF.
The TEQ, calculated by multiplying the TEF
value (Van den Berg et al. 1998) of each spe-
ciﬁc compound by the concentration of that
compound in the mixture, results in the
TCDD equivalent of that compound. For the
TEF mixture, doses were formulated for com-
parison with the 10, 22, 46, and 100 ng/kg
TCDD group by using the WHO TEFs of
1.0 for TCDD, 0.1 for PCB-126, and 0.5 for
PeCDF. Speciﬁc target doses used in the TEF
mixture study were 10 ng TEQ/kg (3.3 ng/kg
TCDD, 6.6 ng/kg PeCDF, 33.3 ng/kg
PCB-126), 22 ng TEQ/kg (7.3 ng/kg TCDD,
14.5 ng/kg PeCDF, 73.3 ng/kg PCB-126),
46 ng TEQ/kg (15.2 ng/kg TCDD,
30.4 ng/kg PeCDF, 153 ng/kg PCB-126), and
100 ng TEQ/kg (33 ng/kg TCDD, 66 ng/kg
PeCDF, 333 ng/kg PCB-126). Control
animals received corn oil:acetone vehicle
(2.5 mL/kg) alone. Batches of actual dosing
formulations used were periodically sampled
and analyzed every 2–3 months by GC/MS
to ensure that they were within 10% of the
target concentration.
Pathology. At necropsy, all tissues were
examined grossly, any lesions observed were
recorded, and a full complement of tissues was
removed and fixed in 10% neutral buffered
formalin for microscopic evaluation. After ﬁxa-
tion, the tissues were trimmed, processed,
embedded in parafﬁn, sectioned at a thickness
of 5 µm, stained with hematoxylin and eosin,
and examined microscopically. The pathology
findings from all studies were subjected to a
full pathology peer review. To ensure consis-
tency of the histopathologic diagnoses among
the TEF dioxin projects, the same study
pathologist, quality assurance pathologist,
pathology working group (PWG) chairperson,
NTP pathologist, and members of the PWG
served in all studies. In addition, diagnostic cri-
teria for the proliferative hepatocellular lesions
were peer reviewed by an external expert panel
advisory board.
Statistical analysis. Dose-specific tumor
incidence was survival adjusted using the
poly-3 adjustment (Bailer and Portier 1988).
Data were modeled using a Hill function, as
described by Toyoshiba et al. (2004), using
the following formula:
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Table 1. Summary of survival-adjusted neoplasm incidences.
Hepatocellular Gingival
Study, dose (ng/kg)a Cholangiocarcinoma adenoma CKE SCC
TCDD (TEF = 1.0)
00 b** 0** 0** 2.5**
3 0 0 0 5.7
10 0 0 0 2.6
22 2.9 0 0 0
46 10.3 2.6 0 10.2
100 54.9** 29.9** 21.1** 22.0**
PCB-126 (TEF = 0.1)
0 0** 3.2** 0** 0**
30 0 5.2 0 2.6
100 2.5 2.5 0 2.5
175 0 0 0 2.7
300 13.6* 5.5 2.7 5.4
550 14.0* 9.7 26.0** 4.7
1,000 60.3** 20.9* 83.5** 20.2**
PeCDF (TEF = 0.5)
0 0* 2.4** 0 2.4
6 0 0 0 5.2
20 0 2.7 0 2.7
44 2.6 0 0 0
92 2.8 5.5 0 2.8
200 5.4 10.9 2.7 8.1
TEF mixturec
0 0** 0** 0** 2.7
10 0 2.5 0 2.5
22 4.8 2.4 0 0
46 17.4 2.5 5.1 0
100 26.0** 31.0** 54.7** 6.0
aAnimals were treated with each compound or a mixture with each respective dose, 5 days/week for up to 104 weeks
(n = 53–55/group). bAll table values represent the poly-3–adjusted neoplasm incidence (%) after adjustment for intercurrent
mortality. cMixture of TCDD, PCB-126, and PeCDF (ng TEQ/kg). *p < 0.05 and **p < 0.01 [in the 0-dose rows, p-values are for
the poly-3 trend test (Bailer and Portier 1988); for other doses, these p-values represent pairwise comparisons between the
individual dose groups and the control group]. where P(dose) is the probability that an ani-
mal will have a tumor, b0 is the background
incidence rate (E0), b2 is the half-maximal
dose (ED50), and b3 is the shape parameter.
Parameters were estimated using maximum
likelihood techniques assuming a binomial
distribution for the tumor counts and their
standard errors estimated using sandwich esti-
mators (Zhang et al. 2000). The relative
potency factor (RPF) of each congener (cong)
is calculated as b2,TCDD/b2,cong. In the full
model (the “independent” model), equation 1
is fit to each congener and to the mixture,
resulting in separate estimates of b0, b2, and
b3 for each of the three congeners and for the
mixture. For the mixture, the dose is an addi-
tive function of the component congener
doses and the ratios of their ED50 values to
that of TCDD (Toyoshiba et al. 2004). With
this formula for the mixture dose, if the con-
geners are dose additive in the mixture, then
the RPF for the mixture will be 1. That is,
b2,Mix = b2,TCDD if the congeners are dose
additive.
Chi-square–based likelihood ratio tests
were used to evaluate all hypotheses. The
hypotheses tested were as follows: 
Same shape: 
b3,TCDD = b3,PCB = b3,PeCDF = b3,Mix and
b0,TCDD = b0,PCB = b0,PeCDF = b0,Mix.
Additivity: same-shape hypothesis and
b2,Mix = b2,TCDD.
WHO: same-shape and additivity hypotheses,
and
b2,PCB = 10 × b2,TCDD, and
b2,PeCDF = 2 × b2,TCDD.
The statistical power of the likelihood ratio
tests was investigated by simulating data using
the maximum-likelihood estimates for the less
restricted model (e.g., additivity) to evaluate
our ability to reject the more restricted model
(e.g., WHO TEFs). The power was found to
be rather small, ranging from 0.1 to 0.5 for
these data and this design.
Results
In all four studies, there were significant
increases in the incidence of both neoplastic
and nonneoplastic effects in several tissues [all
data from these studies are available from the
NTP website (NTP 2004)]. Four speciﬁc neo-
plasms were observed in all of the studies, and
increases in the incidences of these neoplasms
were considered to be related to treatment:
cholangiocarcinoma and hepatocellular ade-
noma of the liver, cystic keratinizing epi-
thelioma (CKE) of the lung, and gingival
squamous cell carcinoma (SCC) of the oral
mucosa (Table 1). In the studies of TCDD,
PCB-126, and the TEF mixture, the incidences
of these neoplasms were signiﬁcantly and dose-
dependently increased over controls. In the
study of PeCDF, the incidence of cholangio-
carcinoma and hepatocellular adenoma showed
a signiﬁcant dose–response trend over the dose
range used, whereas the incidences of CKE and
gingival SCC were not significantly elevated
above controls. Neither CKE nor cholangio-
carcinoma was observed in control animals
from any of these studies.
The incidences of these neoplasms were
used for the dose–response analysis of the
several hypotheses related to the TEF
approach. We tested three hypotheses in this
study. First, we tested whether the shapes of
the dose–response curves were the same across
all four studies for each neoplasm, because
this is a fundamental assumption in the TEF
approach (Van den Berg et al. 1998). To
achieve this, survival-adjusted (Bailer and
Portier 1988) incidence data from the four
studies were modeled using sigmoidal Hill
functions, and differences in model ﬁts were
evaluated by maximum likelihood methods
(Toyoshiba et al. 2004). Initially, each data
set was modeled with parameters describing
the dose response unrestricted, allowing an
independent optimal ﬁt for each chemical or
mixture (Figure 1A). This model was then
compared with a model in which the only
parameter that was unique to each compound
was the ED50 (Figure 1B). By comparing the
error associated with the two model fits, we
tested the null hypothesis that a common
Article | Dioxin TEF evaluation
Environmental Health Perspectives • VOLUME 113 | NUMBER 1 | January 2005 45
Figure 1. Dose–response modeling of fractional poly-3–adjusted tumor incidence showing each data set
under four different model conditions: (A) independent model, (B) same-shape model, (C) additivity model,
and (D) WHO model. Individual dose–response data from each respective study are shown. 
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PCB-126
TCDD
PeCDF
TEF mixture *
+shape model was as good a ﬁt as the optimal
independent fit. This appeared to hold true
(Table 2), indicating that each neoplasm had a
common dose–response shape across all four
studies. The shape of the dose–response curve
for each neoplasm was highly nonlinear (shape
parameter > 1.5). RPFs for each neoplasm
were calculated based on the ratio of the ED50
(e.g., RPF PCB-126 = ED50 TCDD/ED50
PCB-126) (Table 2). In general, the RPFs for
PCB-126 were similar to the WHO TEF
value of 0.1 (0.11, 0.09, and 0.09 for
cholangiocarcinoma, hepatocellular adenoma,
and gingival SCC, respectively), except for the
induction of CKE, where the RPF for
PCB-126 was 0.2.
The second hypothesis to be tested was
whether the increased incidence for the mix-
ture for each neoplasm was consistent with a
potency-adjusted dose-additive combination
of the individual effects of TCDD, PCB-126,
and PeCDF. This was achieved by compari-
son of the additive model to the same-shape
model, for each respective neoplasm (Table 2;
Figure 1C vs. Figure 1B). In both models, the
administered “dose” of the mixture (on a
TEQ basis) was calculated by summing the
optimized RPF-adjusted dose of TCDD,
PCB-126, and PeCDF 
TEQ = {[TCDD] 
+ {[PCB-126] × (1/optimal RPF)} 
+ {[PeCDF] × (1/optimal RPF)}. 
However, the ED50 for the additivity model
uses the ED50 value optimized for the TCDD
data set, whereas in the same-shape model the
ED50 is optimized to the mixture data set. If
dose additivity were true, then the fit of the
dose–response curve for the mixture should
be statistically the same as for TCDD.
For both liver neoplasms, the additive
models could not be rejected (Table 2,
p > 0.05) and showed minimal deviation
from dose additivity. The optimal relative
potencies for cholangiocarcinoma and
hepatocellular adenoma were 0.98 and 1.02,
respectively, compared with the expected
value of 1.0. For CKE of the lung, there was
a 1.2-fold increase over the expected value of
1.0 (Table 2), although this was not signifi-
cantly different at the p < 0.01 level.
Similarly, for gingival SCC the mixture
showed only 47% of the response predicted
under dose additivity (antagonism), but this
was not signiﬁcant at the p < 0.01 level.
Finally, we tested the hypothesis that the
current WHO TEFs for PCB-126 (0.1) and
PeCDF (0.5) (Van den Berg et al. 1998)
could be used rather than the optimal RPFs.
For this test, we compared the fits for the
WHO model and the additive model
(Figure 1D vs. Figure 1C). For the WHO
model, the ED50 for the mixture was forced
to be the same as that of TCDD, and the
RPFs for PCB-126 and PeCDF were fixed
as 0.1 and 0.5 rather than being optimized.
In this case, the models for cholangiocarci-
noma and CKE were rejected (Table 2,
WHO model; p < 0.001). In contrast, the
models for hepatocellular adenoma and gin-
gival SCC were not rejected (Table 2,
WHO model; p > 0.05), indicating that the
dose response for the mixture was consistent
with a TEF-adjusted dose-additive combi-
nation of individual congener effects. For
cholangiocarcinoma, it is likely that the
lower than predicted potency of PeCDF for
this neoplasm (0.16 compared with the
WHO TEF of 0.5) was driving this devia-
tion. Similarly, for CKE, the higher potency
Article | Walker et al.
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Table 2. Dose–response parameter estimates of models.
Independenta
TCDD PCB-126 PeCDF TEF mixture Same shapeb Additivityc WHOd
Cholangiocarcinoma
E0 (%) 0 0 0 0 0 0 0
Shape 2.81 (0.68) 2.23 (0.58) 1.02 (1.1) 1.40 (0.43) 2.02 (0.31) 2.02 (0.3) 1.9
ED50 (ng/kg) 94 (9.0) 928 (112) 3,006 (9,686) 128 (32) 104 (13) 104 (10) 131
RPF, PCB-126 0.10 (0.02) 0.11 (0.02) 0.11 (0.02) 0.10
RPF, PeCDF 0.03 (0.10) 0.16 (0.04) 0.16 (0.04) 0.50
RPF, TEF mixture 0.74 (0.20) 0.98 (0.16) 1.0 1.0
p-Valuee 0.40 0.90 < 10–4
Hepatocellular adenoma 
E0 (%) 0 0.03 0.01 0.02 0.02 0.01 0.01
Shape 3.74 (1.5) 2.24 (1.5) 1.86 (1.9) 4.90 (0.8) 2.95 (0.64) 2.91 (0.7) 2.80
ED50 (ng/kg) 125 (18) 1,896 (1,007) 645 (838) 81 (5) 141 (21) 137 (18) 155
RPF, PCB-126 0.07 (0.04) 0.09 (0.02) 0.10 (0.01) 0.10
RPF, PeCDF 0.19 (0.25) 0.34 (0.08) 0.35 (0.07) 0.50
RPF, TEF mixture 1.54 (0.24) 1.02 (0.18) 1.0 1.0
p-Value 0.17 0.32 0.19
CKE
E0 (%) 0 0 0 0 0 0 0
Shape 23.4 (—)f 4.45 (—)f 16.96 (—)f 4.16 (—)f 4.45 (0.8) 4.57 (0.88) 3.61
ED50 (ng/kg) 121 (—)f 695 (—)f 333 (—)f 110 (—)f 136 (14) 129 (10) 109
RPF, PCB-126 0.17 (—)f 0.20 (0.02) 0.19 (0.02) 0.10
RPF, PeCDF 0.36 (—)f 0.30 (0.08) 0.34 (0.05) 0.50
RPF, TEF mixture 1.27 (—)f 1.21 (0.14) 1.0 1.0
p-Value 0.99 0.033 < 10–4
Gingival SCC
E0 (%) 0.03 0.02 0.03 0.01 0.02 0.02 0.02
Shape 2.14 (—)f 2.42 (—)f 5.54 (—)f 26.6 (—)f 2.35 (1.0) 2.72 (1.0) 2.90
ED50 (ng/kg) 188 (—)f 1,905 (—)f 331 (—)f 116 (—)f 171 (51) 168 (38) 195
RPF, PCB-126 0.10 (—)f 0.09 (0.02) 0.09 (0.02) 0.10
RPF, PeCDF 0.57 (—)f 0.26 (0.12) 0.24 (0.14) 0.50
RPF, TEF mixture 1.62 (—)f 0.467 (0.25) 1.0 1.0
p-Value  0.93 0.047 0.07
SEs of parameter estimates are shown in in parentheses.
aEach curve had independent parameter estimates. bThe whole data set was modeled under the assumption that there is a common E0 and shape parameter across all four studies.
cThe whole data set was modeled under the assumption that there is a common E0 and shape parameter across all four studies and that the ED50 for the mixture is based on dose addi-
tivity of the constituents (such that the RPF for the mixture is 1.0). dThe data were modeled assuming additivity and that the relative potencies for PCB-126 and PeCDF were equivalent to
the WHO TEFs. eLikelihood ratio test (analysis of the same-shape model was relative to the independent model; analysis of the additivity model was relative to the same-shape model;
analysis of the WHO model was relative to the additivity model). fReliable SEs could not be calculated due to instability of the model. of PCB-126 and lower predicted potency of
PeCDF resulted in this rejection.
Discussion
The main objective of the present study was to
test the hypothesis that the increased tumor
incidence observed with a mixture of dioxins
could be predicted based upon the potency-
adjusted dose-additive effect of the individual
compounds present within the defined mix-
ture. A key assumption in this approach is that,
across the different studies, the shape of the
dose–response curves for the increased inci-
dence of each respective neoplasm is funda-
mentally the same. This was indeed the case,
indicating that it is appropriate to describe the
relative carcinogenicity of each compound/
mixture by the ratio of their ED50 values to
that of TCDD. Furthermore, we showed that
the observations seen for the mixture for each
of the four neoplasms were, in general, consis-
tent with the potency-adjusted dose-additive
effects seen individually for TCDD, PCB-126,
and PeCDF. Finally, we showed that for hepa-
tocellular adenoma and gingival SCC, the
effects seen for the mixture were generally con-
sistent with the use of the WHO TEF values
(Van den Berg et al. 1998) of 0.1 and 0.5 for
PCB-126 and PeCDF, respectively. Moreover,
although the use of the WHO TEFs for
increased incidences of cholangiocarcinoma of
the liver and CKE of the lung was statistically
rejected, the estimated potency of the mixture
relative to TCDD alone for these sites was
0.98 and 1.21, respectively, only marginally
different from the expected value of 1.0.
It is important to note that the current
WHO TEFs are based on an expert evaluation
of individual studies that examined the relative
potency of a given chemical to the reference
compound, TCDD, which is assigned a
potency of 1 (Van den Berg et al. 1998). TEF
values are an order of magnitude estimate of
the overall “toxic potency” of a given com-
pound and therefore do not speciﬁcally refer
to the potency from any single study with a
particular end point. By comparison, an RPF
is determined for a speciﬁc chemical in a sin-
gle study relative to a specific end point.
Consequently, it was expected that the esti-
mated potencies would not be identical to the
WHO TEF values. It is noteworthy that
although RPF values for other end points used
for the derivation of TEFs span several orders
of magnitude, in general the RPFs for each
compound across different sites varied less
than half an order of magnitude.
From these analyses, it is evident that the
current WHO TEF value of 0.1 for PCB-126
is an appropriate value. For cholangiocarci-
noma, hepatocellular adenoma, and gingival
SCC, the optimal potencies of PCB-126 were
0.11, 0.09, and 0.09, respectively. The opti-
mal potency for induction of CKE was 0.20.
The increased potency for the mixture
appeared to be due to a higher than predicted
observed potency of PCB-126 for this site
(0.21 compared with its WHO TEF of 0.1).
Although use of an overprediction of potency
would ultimately be protective of human
health when used in a risk assessment setting,
an underprediction of risk would be less pro-
tective. Additional research is required to
understand the pathogenesis of these squa-
mous neoplasms and if this may be related to
human lung cancer risk. 
For PeCDF, it appears that the current
WHO TEF of 0.5 (Van den Berg et al. 1998)
somewhat overestimates its potency for all the
analyzed neoplasms. For cholangiocarcinoma,
hepatocellular adenoma, CKE, and gingival
SCC, the optimal potencies of PeCDF were
0.16, 0.34, 0.30, and 0.26, respectively. This
suggests that the current TEF value for PeCDF
ought to be reevaluated for its application in
quantitative cancer risk assessments. The lower
potency of PeCDF observed here is consistent
with earlier work on the promotion of altered
hepatocellular foci in rat liver in a two-stage
initiation–promotion model of hepato-
carcinogenesis (Waern et al. 1991). In that
study, the authors estimated that the potency
of PeCDF relative to TCDD was approxi-
mately 0.1, when based on weekly adminis-
tered dose after an initial loading dose.
Although it is beyond the scope of this arti-
cle to fully compare the present TCDD study
with previously reported studies of dioxins and
PCB mixtures, in general the site speciﬁcity of
effects from these studies was consistent with
those prior studies with TCDD and related
compounds. In the feed study of TCDD con-
ducted by Dow Chemical Company, Kociba
et al. (1978) observed increased incidences of
neoplasms in the liver, lung, and hard palate.
The increased incidence of cholangio-
carcinoma that was seen in the present series of
studies has not been seen before in cancer
bioassays of DLCs or PCB mixtures. A detailed
comparison of study design issue and compara-
tive dose–response modeling of data from these
studies will be reported separately.
Although the focus of the data reported
here was evaluation of carcinogenicity, we have
previously reported on the examination of
induction of cytochrome P450 data from ani-
mals killed at interim time points during the
conduct of these studies (Toyoshiba et al.
2004). In that analysis, we found that in general
there was lack of support for common dose–
response shape for induction of CYP1A1 and
CYP1A2 in the liver and CYP1A1 activity in
the lung. Moreover, when modeling the data
under the assumption of common shape, there
was in general a lack of dose additivity for the
mixture. This appeared to be driven for the
most part by the dose response for induction of
P450 by PeCDF, which showed higher levels of
induction of P450 than the other compounds.
PeCDF can sequester in the liver at high levels,
leading to high body burdens of this compound
at higher doses. Given that the induction of
these P450s is tightly linked to tissue levels of
the compound, the variation in dose response
likely reflects differences in short-term
pharmacokinetics and pharmacodynamics. In
contrast, neoplasia in these studies appears to be
a more protracted response that requires longer
durations of constant exposure. Hence, phar-
macokinetic and pharmacodynamic differences
between the compounds may not be as inﬂuen-
tial on the ultimate dose–response models.
The data presented here support additiv-
ity for compounds whose primary mecha-
nism of action is via the AhR. However, it
was not designed to address additivity for
compounds that may have multiple modes of
action that are also included in the current
TEF scheme, for example, mono-ortho-PCBs
(e.g., PCB-118). In addition, because expo-
sure to PCBs always occurs as a mixture, this
study was not designed to address whether the
potency of a DLC is affected by non-DLCs
such as the di-ortho-PCBs (e.g., PCB-153).
To this end, additional studies as part of this
evaluation of the dioxin TEF scheme being
conducted by the NTP are examining the car-
cinogenicity of PCB-153 and PCB-118 and
also mixtures of PCBs (PCB-126 and
PCB-153, and PCB-126 and PCB-118).
In summary, to our knowledge this is the
first study that has systematically examined
the specific interactions within a mixture of
compounds in the context of the chronic
rodent carcinogenicity bioassay. The main
conclusion from this study is that we cannot
reject the hypothesis of potency-adjusted dose
additivity for induction of rodent neoplasms
for a deﬁned mixture of DLCs. Moreover, the
optimal potency of the defined mixture was
almost the same as for TCDD alone. These
analyses underscore that the use of TEFs and
dose additivity for assessing mixtures of per-
sistent AhR ligands is reasonable for cancer
risk assessments and is now supported by
some experimental evidence.
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